Is a Beat Likely for Moderna (MRNA) This Earnings Season?

Published on February 21, 2022

Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the fourth-quarter earnings call that reduce its dependence on Spikevax.

Continue reading on website
Other news

Here's Why You Should Hold on to STERIS (STE) Stock for Now

February 21, 2022
Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.

Why Quanta (PWR) is Poised to Beat Q4 Earnings Estimates

February 21, 2022
Higher contribution from the Electric Power Infrastructure Services unit is likely to aid Quanta Services' (PWR) Q4 results.